+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 878 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effect of a chewing gum containing an active compound called MIIP-E2 on dental plaque formation using a 4-day plaque accumulation model. This single-blind, randomized controlled trial involves 32 adult subjects who will participate in three treatment periods, each lasting four days. The study compares an active MIIP-E2 gum, a placebo gum without the active compound, and a no-gum control regimen to assess their impact on dental plaque buildup. The trial uses a 3-way crossover design where each participant experiences all three treatments in different sequences, with approximately 10-day washout periods between treatments. During each 4-day treatment period, participants will refrain from oral hygiene practices and use the assigned gum product three times daily for 10 minutes after meals, chewing on each side of the mouth for one minute before chewing freely. Compliance will be monitored using daily diaries. Participants will undergo oral examinations, plaque assessments, saliva sample collections, and intraoral photographs at baseline and after each treatment period. The primary outcome is the amount of dental plaque measured after four days of intervention. Additional assessments include DNA sequencing of oral bacteria and visual plaque evaluations. The study includes safety and compliance checks and lasts through the three treatment periods with washouts in between.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are investigating whether the supplement 5-hydroxytryptophan 5HTP, derived from the plant Griffonia Simplifolia, can improve lung function and reduce anxiety symptoms in children aged 8 to 18 with mild to moderate allergic asthma. This study is a randomized, triple-blind, phase 2 trial comparing 5HTP against a placebo and aims to better understand how 5HTP affects lung inflammation, blood eosinophil levels, and anxiety or depression scores. Participants will receive either 5HTP or a placebo for a 28-day dosing period followed by a 3-week washout period before switching to the other treatment group. Dosage is based on weight, with those under 100 pounds receiving 50mg twice daily and those over 100 pounds receiving 100mg twice daily. The study includes five visits over approximately 12 weeks, allowing researchers to observe the effects of both treatments in a crossover design. During the study, participants will undergo pulmonary function tests to measure forced expiratory volume FEV1 and blood tests to count eosinophils. Questionnaires will assess changes in anxiety and depression symptoms. The study carefully monitors participant safety and adherence, with informed consent required from participants and guardians. The total study duration for each participant is about 12 weeks, with multiple assessments throughout this period to evaluate treatment impact and safety.

Age: 8Years - 18YearsAll GendersPhase 2
1 location
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.

Age: 18Years - 80YearsAll GendersPhase 3
109 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and how the body processes a medication called NXT007 compared with another treatment called emicizumab for people aged 12 years and older who have severe or moderate congenital hemophilia A without inhibitors or any severity of hemophilia A with inhibitors. The study is a Phase III clinical trial focused on treatment to understand these two prophylaxis options better. Participants are randomly assigned to receive either NXT007 or emicizumab prophylaxis during the main treatment period. Emicizumab is given with a loading dose of 3 mgkg weekly for 4 weeks, followed by maintenance doses at different intervals, while NXT007 is administered subcutaneously as an integrated drug-device product. After the main treatment period, participants on NXT007 can continue this treatment, and those on emicizumab can switch to NXT007 during an open-label extension phase. During the study, participants will be monitored for bleeding rates, treatment burden, and safety through various assessments including questionnaires and blood tests. Researchers will track adverse events, immune responses to NXT007, and drug levels over approximately 3.5 years. The primary measure is the annualized rate of treated bleeds from month 2 onward, with study completion expected in 2032.

Age: 12Years +All GendersPhase 3
63 locations
S

Actively Recruiting

Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.

Age: 18Years +FEMALEPhase 3
167 locations
W

Actively Recruiting

Researchers are evaluating a culturally-tailored home-based physical activity program designed for Hispanic or LatinoLatina adolescent and young adult childhood cancer survivors. These survivors may face long-term effects like weight gain, fatigue, and reduced physical fitness after cancer treatment. The study aims to see if this culturally-relevant program can help increase physical activity and improve overall health compared to using a Fitbit tracker alone. The study has two stages. In Stage 1, 20 Latinx survivors participate in developing the intervention using Fitbit trackers, text messages, social media support, wearable activity devices, and interviews over 9 months. In Stage 2, 170 survivors who do not meet physical activity guidelines are randomized to either the intervention group, which includes Fitbit use, weekly goal-setting, peer support via social media and Zoom meetings, and optional activity partners, or a control group that only uses Fitbit trackers for 12 weeks. The intervention includes an intensive phase with weekly sessions followed by a 4-week maintenance phase. Participants will wear Fitbit trackers daily and engage in goal-setting, peer discussions, and physical activity reminders. Researchers will measure moderate to vigorous physical activity, sedentary time, and health-related quality of life over 12 weeks. Additional evaluations include physiological markers of heart and metabolic health and qualitative interviews to improve the program. The study lasts through the intervention phases with ongoing monitoring and support for participants.

Age: 15Years - 20YearsAll GendersPhase 2
77 locations
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a device called RD2 Ver.02 compared to a control treatment for managing transsphincteric and long intersphincteric anal fistulas. The study aims to assess the complication rate within 6 months, recurrence rates at 12 months after treatment, and the incidence of perirectal infection by 6 months. This is a prospective, multi-center, double-blind, randomized controlled trial conducted by RedDress Ltd. Participants will be randomly assigned to one of two groups. Both groups will undergo debridement of the fistula tract, suturing of the internal opening, and a water leak test to ensure sealing. In the treatment group, the patients own coagulating blood RD2 Ver.02 will be applied inside the fistula tract to serve as a provisional matrix. In the control group, the blood sample will be discarded, and saline will be applied instead. Treatments are performed in the operating room. Participants will be monitored for healing and complications through 6 to 12 months post-treatment. The primary outcome is the combined healing rate of anal fistulas at 6 months. Secondary outcomes include clinical recurrence at 12 months and incidence of perirectal infections at 6 months. Blood samples, clinical evaluations, and imaging pelvic MRI are used to assess eligibility and monitor safety and efficacy. The trial will continue enrollment and follow-up until June 2028.

Age: 18Years +All GendersPhase Not Applicable
10 locations
M

Actively Recruiting

Researchers are studying KK8123 in adults with X-linked hypophosphatemia XLH to evaluate its safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD. This Phase 12, multicenter, open-label study includes a screening period, dose escalation, and an optional safety extension. The goal is to understand how KK8123 behaves in the body and its effects on XLH symptoms. Participants will receive subcutaneous doses of KK8123 in escalating amounts during Part 1, which includes a treatment period followed by observation. Part 2 offers an optional extension to continue safety monitoring. Doses range from low to mid-high levels, and the study assesses various biological markers and labs over a period of up to 48 weeks. During the trial, participants undergo regular assessments including blood tests for phosphorus levels, hematology, clinical chemistry, hormone levels, vital signs, echocardiograms, and renal ultrasounds. Researchers monitor for treatment-emergent adverse events and measure drug concentration levels. The study lasts up to 48 weeks with continuous safety and efficacy monitoring throughout the treatment and extension phases.

Age: 18Years - 65YearsAll GendersPhase 1Phase 2
10 locations
L

Actively Recruiting

Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.

Age: 18Years +All GendersPhase 3
118 locations

1-10 of 878

1